Introduction
Lung transplantation is a lifesaving therapy for patients with end-stage lung diseases; however, primary graft dysfunction (PGD) limits successful clinical outcomes. PGD is a multifactorial acute lung injury that may develop after lung transplantation (1) and is characterized by progressive hypoxemia and radiographic pulmonary infiltrates. Severe PGD (International Society for Heart and Lung Transplantation grade 3 classification) is defined as the ratio of PaO 2 /fraction of inspired oxygen (P/F) <200 mmHg with the presence of pulmonary infiltrates and affects 10-25% of all lung transplant patients (2) . PGD is also associated with decreased 30-day mortality (3), reduced long-term survival (4), and increased incidence of chronic allograft dysfunction (5) .
Ex vivo lung perfusion (EVLP) is a system that allows for the assessment of a donor lung via ventilation and perfusion of the procured donor lung ex vivo. We conducted the first clinical trial for EVLP and found that the Toronto normothermic EVLP technique provides an opportunity to effectively assess marginal donor lungs (6) . In these lungs, the incidence rate of PGD after EVLP and transplantation is similar to the rates found after conventional lung transplantation. We used 4-6 h of EVLP to evaluate donor lung quality through physiological function and physical examination, including bronchoscopy, x-ray, and direct palpation and inspection. The assessment of donor lung quality using EVLP could be further improved by combining its use with the detection of injury-associated biomarkers.
Adhesion molecules on the vascular endothelium surface play an important role in leukocyte-endothelial adhesion in the inflammatory response (7) (8) (9) . Adhesion molecules are upregulated on the membrane of activated endothelium in response to stimulation by inflammatory cytokines or endotoxins. These molecules are susceptible to proteolytic cleavage and subsequently are shed from the endothelial cell surface into circulation. The levels of soluble forms of adhesion molecules, including soluble intercellular adhesion molecule 1 (sICAM-1), soluble VCAM-1 (sVCAM-1), and soluble E selectin (sE selectin), are correlated with their membrane-bound expression and provide an index for endothelial activation (10) (11) (12) (13) (14) .
We hypothesized that circulating adhesion molecules, as markers of endothelial activation, in EVLP perfusate might reflect PGD-associated donor lung injury before transplantation and thus potentially predict posttransplant outcomes.
Materials and Methods

Clinical EVLP technique
The details of our acellular normothermic EVLP technique have been described previously (6, 15) . In brief, donor lungs were procured in a standard fashion, transported from the donor hospital to our center under standard conditions of cold storage in a low potassium dextran solution (Perfadex; XVIVO Perfusion, Denver, CO), and placed in the Toronto EVLP circuit. The circuit was primed with 2 L of perfusate (Steen Solution; XVIVO Perfusion). This solution is a buffered dextran containing an extracellular-type solution with an optimized colloid osmotic pressure developed specifically for EVLP. In addition, 500 mg of methylprednisolone (Solu-Medrol; Sandoz Canada, Boucherville, Canada), 500 mg of imipenem/cilastatin (Primaxin; Merck, Whitehouse Station, NJ), and 3000 IU of heparin (Organon Canada, Scarborough, Canada) were added to the perfusate. After the first hour of EVLP, 500 mL of circulated perfusate was removed and replenished with 500 mL of fresh solution. Subsequently, 250 mL was exchanged every hour until the end of EVLP. The rationale of replacement of fluid is to avoid the build-up of products that are potentially harmful to the donor lung and to replenish with fresh perfusate. The organs were perfused for 4-6 h with hourly functional assessments. Lungs with P/F ≥300 mmHg and stable or improving pulmonary artery pressure, airway pressures, and dynamic compliance were considered transplantable. Lungs were excluded for transplantation if the DP/F was <300 mmHg or if they demonstrated >15% deterioration in the other functional parameters or any clinical sign of lung injury (i.e. worsening edema, copious purulent secretion suggesting infection, or bronchial erythema suggesting aspiration).
Patient selection and sample collection
This was a retrospective cohort study of patients transplanted in the Toronto Lung Transplant Program. From September 2008 to August 2013, 100 high-risk donor lungs were subjected to EVLP. The patient selection chart is shown in Figure 1 . The transplanted group (n = 45) included both the PGD (n = 11) and non-PGD (n = 34) groups. Single or nonbilateral (unilateral transplantation, bilateral transplant including any type of lobar transplant) lung transplantation were excluded because the definition of PGD grading is not established in these cases. Recipients with a pretransplantation extracorporeal lung support system (ECLS) were also excluded because PGD grading is strongly affected by this recipient factor regardless of donor lung quality; the use of ECLS postoperatively, which is frequently necessary if used preoperatively, is defined as PGD grade 3 in the International Society for Heart and Lung Transplantation grading system for PGD (1) .
End of follow-up was December 2013. High-risk donor lungs were defined as those that were characterized by any of the following: (a) best P/F <300 mmHg; (b) pulmonary edema detected on the chest x-ray; (c) poor lung compliance during donor operation; (d) donation after cardiac death; and (e) high-risk history, such as multiple (>10 U) blood transfusions or a history of aspiration. Donor lungs with established pneumonias, gross contusions in more than one lobe, and evidence of aspiration of gastric contents were excluded. EVLP perfusate was obtained at 1 and 4 h of EVLP, before the designated exchange of solution. Specimens were immediately snap-frozen and stored at À80°C until analysis. The primary outcome was PGD grade 3 within 72 h after transplantation. Secondary outcomes were duration of mechanical ventilation, intensive care unit (ICU) stay, and survival.
Quantitative enzyme-linked immunosorbent assay
The sICAM-1 was measured by the Human ICAM-1/CD54 Allele-specific Quantikine enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Inc., Minneapolis, MN), sVCAM-1 was measured by a human Figure 1 : Participant enrollment. Pretransplantation ECLS and nonbilateral (unilateral transplantation, bilateral transplant including any type of lobar transplant) patients were excluded to ensure balanced comparison. Patients whose samples were not available were also excluded from further analysis. Excluded patients are indicated in red. ECLS, extracorporeal lung support system; EVLP, ex vivo lung perfusion; PGD, primary graft dysfunction.
VCAM-1 ELISA kit (Boster Biological Technology Co., Ltd., Pleasanton, CA), and sE selectin was measured by the Human E-Selectin ELISA kit (RayBiotech, Inc., Norcross, GA). All analyses were performed according to the suppliers' guidelines.
Statistical analysis
Statistics were calculated with GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA) and R (R Foundation for Statistical Computing, Vienna, Austria). A Mann-Whitney test was used for the comparison of soluble adhesion molecule levels, clinical characteristics, and short-term outcomes of the recipients. Holm correction was performed for multiple comparisons in Figures 3 and 4 (B), (D), and (F). For the categorical data describing clinical characteristics, the Fisher exact test was used. The Wilcoxon signed-rank test was used to test the change of values of markers from 1 to 4 h of EVLP. Linear mixed effects (LME) models were used to assess differences in physiological parameters between study groups, allowing for the presence of some missing values and differences in end points. LME models were used for each of two sets of groups (transplanted vs. rejected; PGD vs. non-PGD). These were random intercept models with two fixed-effects terms (group; time), one interaction term (group:time), and one random effect (subject identifier). LME tests were performed in R using the lme4 package (16) . Reported p-values were computed using Kenward-Roger's approximation with the lmerTest package (R package version 2.0-32.2016; https://CRAN.R-project. org/package=lmerTest). Additional p-values, Holm corrections, and likelihood-based 95% confidence intervals are available in Table S1 . A log-rank test was used to compare proportional survival. Simple and multiple logistic regression analyses were performed for markers in association with PGD, with adjustment for known PGD factors (3) as potential confounders. Partial residuals plots and a global test of goodness of fit for logistic regression were obtained using the R package rms (R package version 4.5-0.2016; https://CRAN.R-project.org/package=rms) and are presented in Figure S1 and Table S2 . All p-values were two-sided in tests; p-values ≤0.05 were considered to be statistically significant.
Informed consent
Written informed consent was obtained from the family of the donor and from the recipients for enrollment. The research protocol was approved by the research ethics board at University Health Network (11-0509-AE, 12-5488-TE).
Results
Study group and associated clinical background and outcome
The clinical characteristics of each group are summarized in Table 1 . There were no significant differences among donor characteristics between the non-PGD and PGD groups. Similarly, there were no significant differences in donor characteristics between the transplanted and rejected groups. The ratio of recipients who had a BMI >25 was significantly higher in the PGD group (p = 0.03). Variables are expressed as mean plus or minus standard deviation or as number of patients (percentage of total). Total preservation time includes first cold preservation, EVLP duration, and second cold preservation after EVLP of the lung, which was transplanted as the first lung. The transplanted group includes the non-PGD group plus the PGD group. DBD, donation after brain death; DCD, donation after cardiac death; ECLS, extracorporeal life support system; EVLP, ex vivo lung perfusion; mPAP, mean pulmonary arterial pressure; PGD, primary graft dysfunction.
[9.1%]; p = 0.43). Long-term survival was significantly better in the non-PGD group compared with the PGD group (log-rank test; p = 0.02). Causes of all deaths are summarized in Table 2 .
Physiological changes alone during EVLP did not discriminate PGD in the lungs that were transplanted In a comparison of the transplanted and rejected groups, oxygenation ability of the lung (P/F ratio) was significantly lower in the rejected group (p = 0.0044). The peak airway pressure, pulmonary arterial pressure, and dynamic compliance were not significantly different (Figure 2A ). In the lungs that were transplanted, however, there were no significant differences between the non-PGD and PGD groups for any physiological variable measured, including P/F ratio, peak airway pressure, pulmonary arterial pressure, and dynamic compliance ( Figure 2B ).
Soluble adhesion molecules in EVLP perfusate differentiates study groups Compared with the transplanted group, sICAM-1 levels (median [IQR]) were significantly higher in the rejected group at 1 h ( Figure 3A) and at 4 h of EVLP ( Figure 3B) . Furthermore, sICAM-1 levels in the PGD group were significantly higher than in the non-PGD group at 1 h of EVLP ( . The sVCAM-1 levels in the transplanted group were significantly lower than the rejected group at 4 h ( Figure 3D ) but were not statistically significant at 1 h ( Figure 3C ). Interestingly, the levels of sVCAM-1 found in PGD lungs were closer to those found in rejected lungs and significantly higher than those in the non-PGD group at both 1 h (median: non-PGD Patient is from the PGD group, which is defined as PGD grade 3 at any time point within 72 h after transplantation. EVLP. There were no significant differences in sE selectin levels found across study groups at 1 h ( Figure 3E ) or 4 h ( Figure 3F ) of EVLP.
Levels of sICAM-1, sVCAM-1, and sE selectin significantly increased over time in the EVLP perfusate between 1 and 4 h in all three groups, except for sVCAM-1 in the non-PGD group ( Figure 4A , C, and E); however, the increase in the rejected group was significantly higher than in transplanted groups for sICAM-1.
Levels of sVCAM-1 tended to be higher in the rejected group but did not reach statistical significance. There were no significant differences between the changes in non-PGD and PGD groups ( Figure 4B , D, and F).
sVCAM-1 is associated with PGD, even after adjustment for potential confounders We performed simple logistic regression analyses for prediction of posttransplant PGD (at any time within 72 h after transplant) based on markers and known PGD risks, summarized in Table 3 . We then tested for loss of significance of our markers of interest in a series of bivariable models with these known PGD risk factors (Table 4) . Remarkably, sVCAM-1 at 1 or 4 h remained significant for association with PGD, even after adjustment for recipient BMI (>25), recipient pulmonary fibrosis, use of intraoperative ECLS, or recipient intraoperative mean pulmonary arterial pressure.
Discussion
PGD remains one of the most challenging complications in lung transplantation. Most donor lungs are declined for clinical transplantation because of fear of severe and unpredictable PGD. Because of the lack of established treatments, an important strategy to prevent PGD is avoiding the transplantation of donor lungs that are thought to have a higher risk of PGD. In this study, we showed that although physiological functions of the donor lung assessed during EVLP were not significantly sICAM-1 is shown on a linear scale, whereas sVCAM-1 and sE selectin are depicted on log scales. PGD, primary graft dysfunction; sE selectin, soluble E selectin; sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble VCAM-1. different between the non-PGD and PGD groups, higher sICAM-1 or sVCAM-1 levels in EVLP perfusate were associated with development of PGD after transplantation. These results suggest that these markers could help detect the presence of injury in donor lungs that would not be detected by the current clinical criteria alone. Interestingly, the associations of sICAM-1 and sVCAM-1 with PGD outcome were seen in biomarker levels at 1 h of EVLP. With the development of a rapid molecular diagnostic tool, such as a nanochip (17) , these markers may aid in a more accurate assessment of donor lung and improve overall selection quality, thus potentially reducing PGD incidence. Although the differentiation of their distributions is not sufficiently distinct to make these molecules strong prognostic clinical markers of PGD on their own, their association with PGD makes them good candidates for inclusion in future multivariable modeling, in addition to providing insight into the underlying biology of the injury leading to PGD.
Furthermore, the levels of these markers were even higher in the rejected donor lungs, which deteriorated in physiological function during EVLP, supporting the concept that these are injury-associated markers. Although we cannot know what the posttransplant clinical outcome of rejected lungs would have been, our results suggest that the transplant outcome using these rejected lungs would have been even worse than in the PGD group. This is consistent with our current donor-selection criteria based on physiological function and physical assessment during EVLP being reasonably good at excluding the donor lungs that would have poor posttransplant outcome. Because these criteria are not sufficient to detect all cases of PGD, the additional use of sICAM-1 and sVCAM-1 levels during EVLP may aid in further reducing the incidences in which lungs that are likely to have poor outcomes are not detected by our current criteria.
From a mechanistic point of view, it was suggested that endothelial activation of the donor lung during EVLP is associated with subsequent PGD development. Several basic and clinical studies suggesting that the presence of adhesion molecules is an underlying mechanism of acute lung injury or PGD support our results. In a thoracic irradiation rat model, administration of anti-ICAM-1 blocking antibody attenuated inflammatory cell infiltration into the lung, and transgenic mice with no ICAM-1 activity did not develop an inflammatory response in the lung after radiation injury (18) . Also in a rat lung transplant model, antisense oligonucleotide therapy for ICAM-1 into the pulmonary vasculature during preservation time leads to reduced expression of ICAM-1 in the endothelium, improved lung oxygenation, and amelioration of the posttransplant inflammatory reaction (19) . These studies suggest that the expression of ICAM-1 in the endothelium plays an important role in the initiation of the lung injury. In a clinical study, early elevation of sICAM-1 in the plasma of pediatric patients with acute lung injury was associated with an increased risk of death or prolonged duration of mechanical ventilation (20) . sVCAM-1 and sICAM-1 in the serum and bronchial alveolar lavage of a patient at risk for acute lung injury and measured within 2 h after admission provides good negative predictive value for subsequent development of acute respiratory distress syndrome (21) . In a lung transplant clinical study, Covarrubias et al showed that circulating sICAM-1 levels in recipient plasma after lung transplantation were higher in patients with PGD, suggesting that the upregulation of ICAM-1 is part of the mechanism of PGD (22) .
The levels of all three soluble adhesion molecules in perfusate significantly increased over time except for sVCAM-1 in the non-PGD group, indicating continuous release of these molecules from the isolated lung during EVLP. Because EVLP is an isolated system without connection to other organs for clearance of molecules in the circuit, these molecules may accumulate in the perfusate rather than as a consequence of EVLP-induced injury to the lung or the pulmonary vasculature. In fact, the transplant outcomes using donor lungs after EVLP were similar to those of conventional transplant without EVLP (6) . Consequently, an increasing marker does not necessarily mean an inflicted injury during EVLP. The finding that sICAM-1 change was significantly higher in the rejected group than the transplanted group suggests that rejected lungs may have more severe lung injury derived from the donor condition. Moreover, the levels of sICAM-1 were significantly different only at 1 h of EVLP, not at 4 h. If we assume that the differences in sICAM-1 at the beginning of EVLP may reflect the injury of donor lung prior to EVLP, the less significant difference may represent a repair process, as we frequently see improvement of organ function through EVLP (6) . Of course, this speculation needs to be tested further.
This study is limited by its small sample size. To validate the predictability of markers for PGD, further study will be warranted with a separate cohort. There were more recipients with higher BMI in the PGD group than the non-PGD group and relatively more recipients with pulmonary fibrosis in the PGD group, even though it did not reach statistical significance. To overcome these confounding factors, we performed multiple logistic regression analyses. After adjusting for these and other factors, the sVCAM-1 levels at either 1 or 4 h still showed predictive values for the development of PGD, supporting this particular soluble molecule as a valuable candidate for further validation.
Conclusions
Soluble adhesion molecules in EVLP perfusate are associated with PGD after lung transplantation. Donor lungs that are likely to develop PGD or to deteriorate during EVLP may have activated endothelium.
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